In 2006, Eason received a report indicating she had breast cancer, and she said she was told she should have both of her breasts removed. She said she sought a second opinion, but the next doctor she consulted relied on the same set of records as the first and reiterated her cancer diagnosis.
A state report blamed the mix-up on a technician who admitted cutting corners while labeling tissue specimens. Both this technician, as well as the doctor who signed off on Eason's diagnosis, no longer work for the company, according to statements by CBLPath's chief executive William Curtis.
When contacted, CBLPath spokespersons declined to comment on the case. However, they cited a statement issued by the company Oct. 3 that noted that CBLPath cooperated with New York state authorities to ensure all appropriate patent care and safety measures were in place.
"After their investigation, the New York State Department of Health found no systemic problems, and no deficiencies were cited against the lab," the statement reads.
"I remember the words, 'You don't have breast cancer, you never did,'" Eason told ABC's "Good Morning America" Oct. 4. "I have a philosophy that you have to laugh to keep from crying, so I try to laugh as much as I can."
But the outcome of Eason's case will no doubt leave her -- and many other women -- worried over the safeguards routinely used at such labs.
"Second opinions are good, but second biopsies are better," she said.
Reporting from "Good Morning America" was also used in this report.